- JP-listed companies
- TMS Co., Ltd
- Financials
- Net income margin (%)
TMS Co., Ltd【JP:4891】
Market cap
¥6.2B
P/E ratio
Timbs Inc. develops anti-inflammatory drugs from black mold compounds, targeting diseases like stroke and inflammatory conditions through partnerships with major pharmaceutical companies.
| Period End | Net income margin (%) | YoY (%) |
|---|---|---|
| Feb 28, 2022 | 55.3 | +194.57% |
| Feb 28, 2019 | 18.8 | -100.01% |
| Feb 28, 2018 | -298,197.9 |